Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Avricore Health Inc V.AVCR

Alternate Symbol(s):  AVCRF

Avricore Health Inc. is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at advancing pharmacy practice and patient care. The Company is involved in the business of health data and point-of-care technologies (POCT). HealthTab, its flagship offering, is a turnkey point-of-care testing solution that combines point-of-care technologies with a secure, cloud-based platform for tackling pressing global health issues. With just a few drops of blood from a finger prick, the system generates lab-accurate results on the spot and data is reported in real time. The test menu includes up to 23 key biomarkers for screening and managing chronic diseases, such as diabetes and heart disease (e.g., HbA1c, Lipid Profile, eGFR). The HealthTab also has capabilities for bacterial and viral tests, such as strep and COVID-19. The HealthTab platform transforms pharmacies into community point-of-care diagnostic centers.


TSXV:AVCR - Post by User

Bullboard Posts
Post by cartoneton Jun 05, 2015 3:13pm
123 Views
Post# 23801911

Cardinal Health to buy generics distributor for $1.12 bln Re

Cardinal Health to buy generics distributor for $1.12 bln Re

Cardinal Health to buy generics distributor for $1.12 bln
Reuters 2 hours ago

 
* Deal gives Cardinal Health more generic volume
 
Alzheimer’s Natural Treatment
Dr Axe Sponsor
* To add more than 15 cents/share to adj profit in 2016 (Adds details, analyst comment)
 
By Amrutha Penumudi
 
June 5 (Reuters) - Cardinal Health Inc said it would buy privately held drug distributor Harvard Drug Group for $1.12 billion to boost volumes of its generic distribution business.
 
The deal comes in the wake of drugstore CVS Health Corp's offer to buy specialty drug supplier Omnicare Inc to expand its ability to distribute drugs to senior care service providers.
 
The Livonia, Michigan-based Harvard Drug Group, a distributor of generic and over-the-counter drugs, had revenue of about $450 million in 2014, Cardinal Health said.
 
"(The deal) adds additional generic volume that Cardinal can leverage by running through its distribution channel and Red Oak venture, and in the process, probably make it quite a bit more profitable," William Blair analyst John Kreger said.
 
The deal will also expand Cardinal's telemarketing division.
 
Cardinal Health, the second-largest U.S. drug distributor by revenue, said it expects the deal to add more than 15 cents per share to adjusted earnings from continuing operations in 2016 and 17 cents per share in 2017.
 
Cardinal Health agreed in March to buy Johnson & Johnson's cardiology and endovascular products unit Cordis for $1.9 billion.
 
The company will fund the deal with existing cash and new debt. It expects to issue $1.5 billion of new debt related to these two acquisitions.
 
The deal is expected to close in the beginning of fiscal year 2016.
 
Cardinal Health said it expects 2016 adjusted earnings from continuing operations to be $4.75-$5.05 per share, largely above the average analyst expectation of $4.89 according to Thomson Reuters I/B/E/S.
 
Jones Day was Cardinal Health's legal adviser on the deal.
 
(Reporting by Amrutha Penumudi in Bengaluru; Editing by Saumyadeb Chakrabarty and Don Sebastian)
Bullboard Posts